Jubilant Pharmova Ltd
JUBLPHARMAJubilant Pharmova Ltd
JUBLPHARMA
Price Chart
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| -152.23 | 1.26 | 1.17% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 44.31 | 5.09 | 0.71% |
Forecast & Ratings
Detailed Forecastfrom 2 analysts
Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Jubilant Life Sciences Limited is a pharmaceutical and life sciences company.
Investor Presentation
View olderPeers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Dr Reddy's Laboratories Ltd
Mankind Pharma Ltd
Torrent Pharmaceuticals Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
All values in ₹
All values in ₹
Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
Earnings Per Share Forecast
All values in ₹
All values in ₹
Income
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 5,934.44 | 5,762.50 | 5,886.29 | 7,557.87 | 9,146.56 | 6,233.67 | 6,389.18 | 6,141.45 | 6,332.31 | 6,555.88 | ||||||||||
Raw Materials | 2,530.06 | 2,157.87 | 2,114.72 | 2,920.96 | 3,523.71 | 1,592.64 | 1,516.38 | 1,550.33 | 1,918.64 | 5,724.28 | ||||||||||
| Power & Fuel Cost | 393.04 | 366.71 | 333.66 | 424.92 | 466.38 | 112.21 | 105.79 | 134.30 | 166.71 | |||||||||||
| Employee Cost | 1,090.28 | 1,125.09 | 1,230.93 | 1,555.88 | 1,925.96 | 1,843.22 | 1,922.88 | 2,043.39 | 2,166.02 | |||||||||||
| Selling & Administrative Expenses | 510.55 | 396.06 | 471.69 | 619.21 | 826.54 | 631.50 | 583.30 | 666.14 | 653.89 | |||||||||||
| Operating & Other expenses | 714.62 | 456.46 | 365.15 | 478.48 | 909.45 | 281.20 | 594.95 | 589.66 | 657.04 | |||||||||||
EBITDA | 695.89 | 1,260.31 | 1,370.14 | 1,558.42 | 1,494.52 | 1,772.90 | 1,665.88 | 1,157.63 | 770.01 | 831.60 | ||||||||||
| Depreciation/Amortization | 287.95 | 346.74 | 291.40 | 415.05 | 370.90 | 339.84 | 348.95 | 381.70 | 554.03 | 551.78 | ||||||||||
| PBIT | 407.94 | 913.57 | 1,078.74 | 1,143.37 | 1,123.62 | 1,433.06 | 1,316.93 | 775.93 | 215.98 | 279.82 | ||||||||||
| Interest & Other Items | 367.61 | 371.35 | 341.11 | 284.28 | 219.81 | 199.71 | 184.10 | 145.49 | 188.20 | 234.29 | ||||||||||
| PBT | 40.33 | 542.22 | 737.63 | 859.09 | 903.81 | 1,233.35 | 1,132.83 | 630.44 | 27.78 | 45.53 | ||||||||||
| Taxes & Other Items | 98.08 | 150.40 | 161.99 | 216.28 | 329.35 | 335.11 | 296.96 | 216.51 | 88.77 | 90.20 | ||||||||||
| Net Income | -57.75 | 391.82 | 575.64 | 642.81 | 574.46 | 898.24 | 835.87 | 413.93 | -60.99 | -44.67 | ||||||||||
| EPS | -3.15 | 21.34 | 31.71 | 35.81 | 31.64 | 48.93 | 48.76 | 25.98 | -3.83 | -2.80 | ||||||||||
| DPS | 2.60 | 2.60 | 2.60 | 2.60 | 3.91 | 4.34 | 5.00 | 5.00 | 5.00 | 5.00 | ||||||||||
| Payout ratio | — | 0.12 | 0.08 | 0.07 | 0.12 | 0.09 | 0.10 | 0.19 | — | -1.78 |
Company Updates
Investor Presentation
Investor Presentation
Investor Presentation
Annual report
PDFAnnual report
PDFAnnual report
PDFPeers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Jubilant Pharmova Ltd | -111.50 | 1.26 | 1.17% |
| Sun Pharmaceutical Industries Ltd | 34.71 | 4.96 | 0.94% |
| Cipla Ltd | 34.93 | 4.13 | 0.70% |
| Dr Reddy's Laboratories Ltd | 21.38 | 4.14 | 0.69% |
Price Comparison
Compare JUBLPHARMA with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Dec 2022
Mar 2023
Jun 2023
Sep 2023
Shareholding History
Mutual Funds Holding Trend
Mutual Fund Holding
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 5 Mutual Funds holding Jubilant Pharmova Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
Nippon India PHARMA FUND DIRECT PLAN GROWTH PLAN - GROWTH OPTION GROWTH Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.3031% | Percentage of the fund’s portfolio invested in the stock 0.37% | Change in the portfolio weight of the stock over the last 3 months -0.01% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 29/33 (-1) |
NIPPON INDIA NIFTY SMALLCAP 250 INDEX FUND-DIRECT PLAN-GROWTH Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.0246% | Percentage of the fund’s portfolio invested in the stock 0.24% | Change in the portfolio weight of the stock over the last 3 months -0.02% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 200/278 (-4) |
Motilal Oswal Nifty Smallcap 250 Index Fund Direct Growth Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.0160% | Percentage of the fund’s portfolio invested in the stock 0.24% | Change in the portfolio weight of the stock over the last 3 months -0.02% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 191/277 (-6) |
Compare 3-month MF holding change on Screener
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Dividend Cuts
JUBLPHARMA has increased or maintained dividend levels over the last 5 years
Dividend Yield
Current dividend yield is 1.17%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹11.71 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateAug 10, 2023
Dividend/Share
₹5.00
Ex DateEx Date
Aug 10, 2023
Cash Dividend
Ex DateEx DateAug 11, 2022
Dividend/Share
₹5.00
Ex DateEx Date
Aug 11, 2022
Cash Dividend
Ex DateEx DateAug 5, 2021
Dividend/Share
₹5.00
Ex DateEx Date
Aug 5, 2021
Cash Dividend
Ex DateEx DateMar 9, 2020
Dividend/Share
₹5.00
Ex DateEx Date
Mar 9, 2020
Cash Dividend
Ex DateEx DateSep 12, 2019
Dividend/Share
₹4.50
Ex DateEx Date
Sep 12, 2019
News & Opinions
Jubilant Life Sciences divests 10% in Safe Foods Corp for Rs 134 cr
2 years ago•Business Today
Jubilant Ingrevia spurts after its Singaporean arm offloads 10% stake of Safe Foods Corp.
2 years ago•Business Standard
Jubilant Ingrevia arm divests 10% stake in Safe Foods Corp for $18.2 mn
2 years ago•Business Standard
Drug makers Granules India, Jubilant Cadista recall products in US market
2 years ago•Economic Times
Drug firms Granules India, Jubilant Cadista recall products in US market
2 years ago•Business Standard
Anurag Roy joins Astec Lifesciences board panel as CEO; Stock dives 4%
2 years ago•India Infoline
Anurag Roy joins Astec Lifesciences as CEO and Whole-time Director; Stock dives 4%
2 years ago•India Infoline
Lower than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of -3.48%, vs industry avg of 8.45%
Decreasing Market Share
Over the last 5 years, market share decreased from 3.72% to 1.98%